ZEVRA THERAPEUTICS, INC.

Analyst Reco. Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-13 EDT			5-day change	1st Jan Change
4.89 ^USD	+1.45%		-5.14%	-25.34%

05-08	Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M	MT
05-08	Transcript : Zevra Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

William Blair Starts Zevra Therapeutics With Outperform Rating	03-12	MT
HC Wainwright Adjusts Price Target on Zevra Therapeutics to $15 From $10, Keeps Buy Rating	12-28	MT
Canaccord Genuity Adjusts Price Target on Zevra Therapeutics to $20 From $19, Keeps Buy Rating	23-08-15	MT
Maxim Starts Zevra Therapeutics at Buy With $12 Price Target	23-03-17	MT
Cantor Fitzgerald Starts KemPharm at Overweight With $20 Price Target	22-11-17	MT
KemPharm Shares Rise After Canaccord Genuity Initiates Coverage	22-09-15	MT
Canaccord Genuity Starts KemPharm at Buy With $20 Price Target	22-09-15	MT
HC Wainwright Cuts KemPharm's Price Target to $10 From $11, Reiterates Buy Rating	22-08-17	MT
HC Wainwright Upgrades KemPharm to Buy From Neutral, Adjusts Price Target to $11 From $10	22-01-31	MT
KEMPHARM : HC Wainwright Adjusts Price Target on KemPharm to $10 From $12, Maintains Neutral Rating	21-04-09	MT
KEMPHARM : HC Wainwright Downgrades KemPharm to Neutral From Buy, Adjusts Price Target to $12 From $24	21-03-04	MT
KEMPHARM : Roth Capital Starts KemPharm at Buy With $28 Price Target	21-01-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW